Literature DB >> 24714450

Kidney protection against ischemia/reperfusion injury by myofibrillogenesis regulator-1.

Xiaoreng Wang1, Tianqi Tao, Rui Ding, Dandan Song, Mi Liu, Yuansheng Xie, Xiuhua Liu.   

Abstract

BACKGROUND/AIMS: Ischemia/reperfusion (I/R) injury is characterized by cytoskeletal reorganization and loss of polarity in proximal tubule epithelial cells. Previously, we showed that myofibrillogenesis regulator (MR)-1 promoted actin organization in cardiomyocytes. MR-1 is also expressed in the kidney.
METHODS: In this study, we investigated MR-1 expression in acute renal failure induced by I/R in Sprague-Dawley rats. We determined the MR-1 expression and the ratio of fibrous actin (F-actin) to globular actin (G-actin). HK-2 cells were treated with or without hypoxia/reoxygenation (H/R), and MR-1 levels were increased by adenoviral overexpression or silenced by RNA interference.
RESULTS: I/R and H/R resulted in cellular injury and decreases of MR-1, the F-/G-actin ratio, and myosin light chain (MLC)-2. MR-1 overexpression attenuated H/R-induced cell injury and loss of surface membrane polarity of actin. MR-1 overexpression also increased the expression and phosphorylation of MLC-2 and MLC kinase, which were decreased in MR-1-silenced and H/R-treated cells.
CONCLUSION: Together, these data show that MR-1 promoted actin polarity on the membrane surface and protected HK-2 cells from H/R injury. The mechanism might involve the rapid organization of F-actin through the upregulation and phosphorylation of MLC-2.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24714450     DOI: 10.1159/000360141

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  1 in total

1.  Calreticulin attenuated microwave radiation-induced human microvascular endothelial cell injury through promoting actin acetylation and polymerization.

Authors:  Feifei Xu; You Wang; Tianqi Tao; Dandan Song; Xiuhua Liu
Journal:  Cell Stress Chaperones       Date:  2016-11-04       Impact factor: 3.667

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.